US market almost needs to be viewed through 2 lenses.
The tech heavy Nasdaq will likely continue to outperform the Dow comprised of the more traditional blue chips.
2nd half year results for those non tech stocks are going to be ugly across the board especiallly the financial sector and with the reality sinking in later this year that a proper vaccine might not be available until this time next year, a second wave in the winter political uncertainty, further lockdowns could all combine to see fears heighten in the markets.
Microsoft should still perform well either way, However Facebook and google are facing dwindling revenue streams and corporate America is presently boycotting facebook and Apple is reliant upon consumer spending so outside of Microsoft those other tech stocks are likely to see some correction which would really see the index take a battering.
Holding covid stocks is a natural hedge and I still see fantastic upside for GDR with the recent partnership announced the road map to commercialisation has been set out here.
All the fun on the main markets could well be over tomorrow
Just seen the Nasdaq and Dow reverse quickly.
Will we.see a flash sell off in the main market in the morning?
Well at least we had one day trying to pretend that Covid fears had gone away.
A vaccine that has completed all the necessary trials to be allowed for general public use is still a good year away at best.
11 countries lined up to purchase our kit.
Come on FDA approval!!!
Yes it is.
Successful drug trials could see this easily at many multiple of present m/cap.
Directors purchases are a strong clue to outcomes.
Absolute nailed on mulitbag opportunity
Any buys below 15p are a steal
Zak is now on board and seeing 20p shortly before news.
Its obvious that successful VAL201 trials sees this mulitbag many times the present SP
Probably the easiest mulitbag on AIM right now.
Time to add a few more before the herd really turn up.
Worried about the potential impact of Covid 19 on your portfolio?
take a look at the following 2 shares:
1) Genedrive (GDR) have a rapid CV19 test about to receive FDA approval and commercial across the USA/India & Africa. Should multi-bag off news of the approvals landing.
2) Valirx (VAL)
A company which has developed a treatment for patients suffering from the after effects of COVID-19 who are experiencing a hyper immune system response. The patient trials results are due September. This one could be a 10-20 bagger on successful trials results.
This isnt a recommendation to sell up all your BOO holdings, but it shouldn't take you too long to research into both companies, and they'll add a natural covid hedge to your portfolio as IF there is a negative impact on the main market due to worsening covid impact globally then these two shares will benefit naturally ahead of their impending news.
I hold a few covid related stocks including SNG which recently rose 500% after successful drug trails.
The UK bio tech sector is particularly hot right now, so doesn't hurt to add a couple of these companies into your portfolio as a natural hedge.
Either way over the near term better than expected results from BOO in September and this will be back well above 400p.
Longer term if BOO demonstrate it's continued YoY growth in line with previous years then this could hit 600p by September next year which is the SP target where the owners (Kumanis) will collect their bonuses (£150m) which no shareholder would begrudge them and represents a ROI of 110% from the present SP.
I'd make sure you stick to companies which offer a combination of value and whose trading is both likely to be unaffected by a ongoing global pandemic but also offer continuous sales growth opportunities.
it's still hard to see much past BOO in the retail sector at present for such a combination.
This is starting to look an even better investment as each day passes in the run up to results.
Now we have a Director adding more shares above the price he paid last month in the placing.
He clearly isnt selling on for a quick 10-20% and wants a bigger slice of the impending action.
Val still under the radar at present but that is definately going to change over the next week or two
I'm definitely adding a few more tranches this week as I view this as one of the biggest multi-bagger opportunities on AIM right now!
If you want to continue this obsession with me Punter... watch this video from GDR and then I'll quiz you on it afterwards.
Anyone who is actually invested in GDR would want to watch this video to help understand their investment here
Watch... and we can all asks you questions later. :-)
I really dont know why you guys bother taking the bait with punters lame posts.
He would love gdr to zig zag up and down infinitum so he carry on the spread betting fun.
All good things come to an end.
We all know approvals and sales will see this take off from here, the market is demonstrating people are accumulating ahead of this.
Absolutely brilliant video and post.
A must watch.. totally get why they invested a little more time in getting the software as good as they have.
I can also see why the labs have been feeding back how easy it is to use the Genedrive kits with the 96 test plate ready mixed vs competitors supplying component regeants that require pre-mixing to a precise instruction which leaves room for error to creep in.
Our 96 test plate looks so easy in comparison..
I'm pretty sure Beckman Coulter are partnering with GDR to roll this out for high throughput solution for mass testing and will be pushing this solution to their existing client base....
They will be selling the benefits as set out below by their president..
Greg Milosevich, President at Beckman Coulter Life Sciences, said: “The integration of Beckman Coulter Life Sciences’ and genedrive’s technologies produces a formidable workhorse solution for specialized laboratories looking to establish new or next level laboratory automation with labor cost reduction. Our ability to fully integrate the RNA extraction process on the Biomek while simultaneously preparing the plates for analysis is a critical step forward in advancing COVID testing workflows. Speed up the testing workflow, reduce labor time and costs. This is the goal of our collaboration with Genedrive and we are excited to be bringing this solution forward to the market.”
Could not agree with you more mate.
See plenty of folk getting locked into companies that they clearly dont or cant understand.
BOO has year on year growth across all KPI's
Fundamentals that any company would die for.
Not a criticism on anyway, but I find it far more important to learn to read and pick apart financial accounts p&l and balance sheet movements combined with sector reports than looking at L2 when making investments decisions
That way you avoid car crashes like AMGO and only pick the winners like BOO for long term investments gains.